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Abstract 
Purpose: Oligo/amenorrhea, as a part of the Female Athlete Triad has adverse 
effects on the athlete’s bone mineral density (BMD) and cardiovascular 
system. Hypoestrogenism, due to suppression of hypothalamus-pituitary axis 
(HPA) as a result of energy imbalance, is the possible cause of the Triad. This 
study was designed based on following up and reassessment of elite female 
athletes who were diagnosed as menstrual dysfunction about two years ago. 
Methods: This study was conducted in three phase sections: 1) Reassess the 
pattern of menstrual cycle among athletes who reported menstrual dysfunction 
about two years ago; 2) Bone mineral density was measured twice in the same 
machine and same center with a two-year interval; 3) The laboratory data 
including blood glucose, lipid profile and inflammatory markers was assessed 
in phase 3. 
Results: BMD of athletes did not change significantly after 25.5 months of 
oligomenorrhea  P (spine) = 0.2, P (femur)=0.9. Mean of all cardiovascular 
factors was in the normal range except for high density lipoprotein (HDL) 
which was 49.28 (SD=9.18), however, most of the athletes had abnormalities in 
their lipid profile. Inverse relationship between the increase in the BMD of 
spine and total cholesterol (r =-0.49, P=0.04), Apolipoprotein A (r = -0.51 
P=0.04), and very low density lipoprotein (VLDL) (r =-0.66, P=0.009). Also 
correlation between BMD of spine and HbA1C (r =-0.70,  P=0.003) were 
significant. 
Conclusion: Findings of this study show that negative changes in BMD and 
cardiovascular biomarkers of female athletes with functional hypothalamic 
menstrual dysfunction could occur if proper therapeutic intervention 
(including increase in calorie intake, decrease in exercise load or hormonal 
replacement) will not consider. 
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INTRODUCTION 
or the first time in early 1990s, the concept of 
Female athlete Triad was introduced to describe 
the interrelated problems of amenorrhea, eating 
disorders and osteoporosis. Based on a new definition 
of the Triad, this syndrome is defined as 
interrelationship among energy availability, menstrual 
function, and bone mineral density (BMD) in 
otherwise healthy female athletes 
[1]. According to this 
classification, low energy availability acts as a primary 
contributor to disruptions in menstrual function and 
other complications. Sustained low energy availability, 
with or without any eating disorder can impair health 
and cause some medical complications in 
cardiovascular, endocrine, reproductive, skeletal, 
gastrointestinal, renal and central nervous systems 
[1,2]. 
Although many athletes may not be concerned about 
short term absence of their menses, the lack of 
estrogen associated with hypothalamus-pituitary axis 
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(HPA) suppression can compromise both bone mineral 
increase during adolescence and young adulthood and 
also maintenance of bone mineral density later in life. 
Indeed the other effect of hypoestrogenism seen in 
amenorrheic athletes is impaired endothelium 
dependent arterial vasodilation 
[3], which decreases the 
perfusion of working muscle, impaired skeletal muscle 
oxidative metabolism 
[4] and elevated low-density 
lipoprotein cholesterol levels 
[5,6]. In other words, 
similar to low BMD, unfavorable lipid profile, and 
increased levels of inflammatory markers may be 
related to menstrual irregularities and estrogen 
deficiency.  Due to the fact that increase of lipid profile 
with different mechanisms can also be the basis for 
early cardiovascular disease, athletes with menstrual 
dysfunction should be assessed more for elevated 
levels of triglyceride and cholesterol to rule out any 
predisposing factor of cardiovascular problems.  
     Even though professional sports for Iranian women 
has newly come to light, the number of female athletes 
who have got permission to attend contests wearing 
Islamic cover in some sport fields at Asian and 
international levels is increasing. This study is part of a 
research which was started in 2007. In the first report 
published by the same researchers in 2009 
[7], it was 
shown that 9% of elite female athletes had been 
suffering from oligomenorrhea or amenorrhea and this 
disorder had had a significantly positive relationship 
with age of under 20 years old, weight class and 
endurance sports, late onset of menarche and use of 
oral contraceptives (OCP). 
     In continuance of this study, to assess the effect of 
duration on the athletes’ health another research was 
designed. Therefore, this study was aimed to evaluate 
these athletes’ menstrual status and their BMD, lipid 
profile, and levels of inflammatory markers to find if 
there is any association between their menstrual 
irregularities and impairment of these components. 
METHODS AND SUBJECTS 
This study is the continuum of a cross sectional 
research by Dadgostar et al 
[7] about the menstrual 
status of all elite Iranian female athletes in 2009. Fifty-
six athletes with functional hypothalamic menstrual 
dysfunction were diagnosed and their BMD was 
examined. After 25.55 (SD=6.15) months, in a new 
study, they were invited to reassess their bone density 
change and cardiovascular health status.  
     Athletes  with  following reasons were excluded 
from this study. 1) becoming eumenorrheic in this 
period of time 2) suffering from chronic diseases, 
including hyperprolactinemia and thyroid disease; 3) 
smoker athletes 4) taking any form of hormonal 
therapy within this time 5) decrease in exercise load 
and having not performed regular exercise (at least 2 
times per week based on reporting from their own 
federation); 6) history of a clinical diagnosis of 
polycystic ovarian syndrome. 
     The study was approved by the ethics committee at 
Tehran University of Medical Sciences. The ethical 
standards of the project were in conformity with the 
provisions of the Declaration of Helsinki of the World 
Medical Association. 
Assessment procedures: 
This study was conducted in three phases. In phase 1, 
we invited athletes to come up to the sports medicine 
clinic of a general hospital. Detailed information about 
their menstrual pattern, exercise records and medical 
history were gathered with a questionnaire which was 
used in previous research 
[7]. Anthropometric findings 
including weight, height, body mass index (BMI) were 
also recorded. In order to reassure that the etiology of 
menstrual dysfunction of our population had not 
changed from two years ago, all laboratory data, 
including serum follicle-stimulating hormone (FSH), 
luteinizing hormone (LH), thyroid-stimulating 
hormone (TSH), prolactin, free T4, serum testosterone 
and dehydroepiandrosterone (DHEA), and an 
ultrasonographic study of the ovary was performed 
again. From a total of 56 elite female athletes 
diagnosed as functional hypothalamic menstrual 
dysfunction, 34 athletes for following reasons were 
excluded from this study: Persons with increase of 
energy intake and decrease in exercise load who started 
to have regular menstruation and/or athletes who used 
OCPs during this time. A total of 22 athletes were 
finally evaluated. Secondary amenorrhea was identified  
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when menses had ceased at a point in time beyond the 
establishment of regular menstrual cycles. In this study, 
secondary amenorrhea is described as the absence for 
more than three months of the menstrual cycle 
[8]. 
Oligomenorrhea was defined as  menstrual cycles 
occurring at intervals longer than 35 days 
[8]. 
     In phase 2, BMD (gram per square centimeter) was 
measured by dual energy X-ray absorptiometry (DXA) 
using a Hologic densitometer (Hologic Discover 
QDR). The measurement parts were the lumbar spine 
(L1-L4) and femoral neck. The results were expressed 
in Hologic standards (driven from the NHANSE III 
study)
 [9]. This assessment was performed by the same 
machine.  Recent guidelines have advocated the use of 
the term “low BMD” instead of osteopenia in 
premenstrual syndrome and the use of Z-scores instead 
of T-scores in young women and children 
[10]. In our 
study, low BMD was defined as a Z-score between -
1.0 and -2.0, and osteoporosis as a Z-score below -2.0. 
Positive diagnosis was defined as low BMD or 
osteoporosis at least one of two measurement areas 
(lumbar spine or neck of femur). The results were 
compared with the previous bone mineral density 
which was performed about 25 months ago.  
     The laboratory data which was measured in phase 
3, was divided in three groups; blood glucose, lipid 
profile and inflammatory markers. Blood glucose was 
evaluated by measurement of fasting blood glucose 
(FBS) and hemoglobin (Hb) A1C. Lipid profile 
included total cholesterol, high density lipoprotein 
(HDL), low density lipoprotein (LDL), very low 
density lipoprotein (VLDL), triglyceride (TG) and 
apolipoprotein (Apo) A and Apo B. Fibrinogen and 
hemocystein took in as inflammatory markers. 
Beckman CX-3 biochemical autoanalyzer (kit for 
HDL, LDL: Pishtaz Teb, for TG , Chol: Parsazmoon, 
for Apo A, Apo B: Randox. 
Statistical analysis: 
Quantitative data were described by mean and standard 
deviation and qualitative data by frequency. T-test and 
chi-square were used to compare quantitative and 
qualitative data respectively. The SPSS program 
(Version 17) was used for all analysis.  
                         RESULTS  
A total of 22 athletes were evaluated. The mean age of 
participants was 23.55(SD=5.47) (range = 16-35). The 
mean BMI was 21.66 (SD= 2.86 kg/m2) (range = 18.21 
- 32.42). Results for low BMD in two measurement 
areas and their comparison are shown separately in 
Table 1 and 2.  
    Based  on  findings  of  bone  mineral  density,  two 
athletes had low BMD (Z score < -2) in femural neck 
and four athletes showed low BMD in their spinal 
region, as the Z score of three of them was between -1 
and -2 and one of them demonstrate Z-score < -2.   
Both BMD of spinal region and femoral neck less than 
-2, belonged to the same athlete. 
        Table 3 shows cardiovascular biomarkers, which 
were measured once after two years of documented 
oligo/amenorrhea. 
    Our data also revealed that the prevalence of high 
levels of total cholesterol; LDL and TG were 15.78% 
(3/19).  HDL lower than 50 was 63.15% (12/19) and  
Table 1:  Distribution of bone mineral density in spine and femural neck 
Bone mineral density  Number  (Percentage) 
Spine  
z score >-1  17 (77.3%) 
z score; -1 to -2  4 (18.2%) 
z score < -2  1 (4.5%) 
Total 22  (100%) 
Femur 
z score > -1  19 (86.4%) 
z score ; -1 to -2  1 (4.5%) 
z score < -2  2 (9.1%) 
Total  22 (100%) 
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Table 2: Comparison mean values of BMD in two separate regions between two years 
Region of BMD 
At the beginning 
N=22 
After 25 months 
N=22 
P value 
Densitometry of spine  1.002 (0.117)  1.012 (0.120)  0.2 
Densitometry of femur neck  0.887 (0.127)  0.878 (0.117)  0.9 
   BMD: Bone Mineral Density 
low Apo A and HbA1C more than 6 were 55.55% 
(10/18) and 31.25% (5/14), respectively. It should be 
mentioned that an HbA1C level more than 7 was 
12.5% (2/16). 
    Our data also revealed that the prevalence of high 
levels of total cholesterol; LDL and TG was 15.78% 
(3/19).  HDL lower than 50 was 63.15% (12/19) and, 
low Apo A and HbA1C more than 6 were 55.55% 
(10/18) and 31.25% (5/14), respectively. It should be 
mentioned that an HbA1C level more than 7 was 
12.5% (2/16). 
        In athletes with menstrual disturbance, we found 
inverse correlation between the rate of increase in bone 
mineral density and total cholesterol (r = -0.49 P= 
0.04), Apo A (r =-0.51, P=0.03), and VLDL (r = -0.66, 
P=0.009). Correlation between the rate of increase in 
bone mineral density and blood lipid levels including 
LDL, TG, HDL, Apo B, and FBS was not significant. 
However, HbA1C was inversely correlated with the 
rate of increase in bone mineral density (r = -0.70, 
P=0.003).  
DISCUSSION 
The design of this study was based on the follow-up of 
elite female athletes who were diagnosed with 
menstrual dysfunction about two years ago. We 
decided to reassess their menstrual pattern and find out 
if the prolongation of the menstrual dysfunction can 
affect their cardiovascular biomarkers and/or change 
their previous BMD which was measured about two 
years ago. To the best of our knowledge, this is the first 
study to evaluate alteration of BMD and its association 
with cardiovascular biomarkers among an Iranian elite 
female athletes group with menstrual dysfunction. 
Findings of this study show that changes in BMD and 
cardiovascular biomarkers of female athletes with 
functional hypothalamic menstrual dysfunction could 
occur if proper therapeutic intervention (including 
increase in calorie intake, decrease in exercise load or 
hormonal replacement) are not considered. We also 
found an inverse relationship between the rate of 
increase in bone mineral density of spine region and 
Table 3: Mean (SD) of Blood glucose, serum lipids and inflammatory biomarkers in female athletes with menstrual dysfunction 
Variables 
Low BMD  
(n=4) 
Normal BMD 
(n=14) 
Normal range (mg/dl) 
Fasting blood sugar  87.33 (10.26)  88.30 (6.97)  70- 115 mg/dl 
Hemoglobin A1C  5.63 (1.27)  5.38 (0.98)  4- 6% 
Total cholesterol  193.00 (52.64)  166.80 (30.73)  Up to 200 mg/dl 
Triglyceride  100.75 (86.93)  78.80 (36.46)  Up to 150 mg/dl 
Low density lipoprotein  83.75 (22.16)  78.07 (17.88)  Up to 130 mg/dl 
Very low density lipoprotein  44.67 (33.08)  39.33 (16.98)  Up to 40 mg/dl 
High density lipoprotein  51.00 (12.06)  49.53 (8.86)  ≥ 35 mg/dl 
Apolipoprotein A  155.50 (53.51)  125.42 (29.14)  120-176 mg/dl 
Apolipoprotein B  96.00 (10.80)  70.17 (15.58)  63-114 mg/dl 
Homocysteine   9.95 (1.48)  11.02 (2.98)  5- 15 µmol/L 
Fibrinogen   274.00 (132.94)  215.79 (35.98)  200-400  /dl 
     SD: Standard Deviation / BMD: Bone Mineral Density 
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total cholesterol and VLDL levels of elite female 
athletes. Although physical activity can maintain and 
increase BMD, the important question asked by a 
health professional is if this generalization can be 
applied to high risk female athletes or not 
[11]?  
     The mechanism for low BMD and an impaired lipid 
profile in athletes with menstrual dysfunction is 
probably related to hypoestrogenism. Previous studies 
have shown that bone mass is affected by the length 
and severity of menstrual dysfunction 
[12]. Due to the 
fact that the peak bone mass gain in a human being 
occurs during the second and third decade of his/ her 
life, lower bone density in athletes with functional 
hypothalamic menstrual dysfunction may predispose 
them to some complications like stress fracture and/or 
osteoporosis which can disturb their function. 
Moreover, it has previously been demonstrated that 
increased levels of lipid profile such as total 
cholesterol, LDL and VLDL are associated with 
hypogonadal states, such as in anorexia nervosa and 
athletic amenorrhea 
[13,14]. 
     Our finding is consistent with the finding of several 
studies whose authors 
[15,16]  have reported non-
significant increases in BMD of athletes who have not 
taken an appropriate therapy. The prevalence of low 
BMD in healthy young females has not been broadly 
studied and there are limited normative databases to 
offer reference norms for this age group 
[11]. In a study 
reported by Cobb et al, athletes 
[17] with persistent 
menstrual dysfunction who did not receive OCs, did 
not have any change in their bone mass, which is in 
agreement with our study. Gibson et al, also found that 
female athletes with menstrual dysfunction after 9-12 
months showed significantly lower BMD than the 
eumenoric group 
[18]. Due to the fact that the etiology 
of bone loss is multifactorial, measurement of bone 
density can be helpful to convince high risk athletes 
into intervention in terms of increasing nutritional 
intake, decreasing intensity of exercise or prescribing 
hormone replacement therapy. 
          Elevated lipid levels may be reported in 
premenstrual women with hypoestrogenic conditions 
secondary to caloric deficiency such as anorexia 
nervosa 
[13,14]. Based on findings by Friday et al 
[19], 
increased level of LDL profiles in amenorrheic athletes 
comparing with eumenorrheic athletes have been 
described. Consistent with these studies, our finding 
shows inverse relationship between the rate of increase 
in bone mineral density and total cholesterol and 
VLDL levels of elite female athletes. The main cause 
of amenorrhea in athletes seems to be an inhibition of 
the hypothalamus-pituitary-ovarian axis and it might 
be that prolonged exercise-induced amenorrhea has 
adverse cardiovascular consequences 
[20,21]. As a rule, 
we consider a physically active lifestyle to be 
defending against the development of atherosclerosis. 
Although the amenorrheic athletes are hypoestrogenic, 
the range of their age, physical activity and also their 
health condition usually protects them from 
cardiovascular disease.  
    Unlike authors of some studies 
[22,23] we not only did 
not find any relationship between alteration of BMD 
and serum level of LDL, but also there was an 
inversely correlated with the rate of increase in bone 
mineral density and serum concentration of Apo A. 
Although estrogen is known to decrease low-density 
lipoprotein (LDL) oxidation 
[22], which are critical 
steps in the progression to atherosclerosis , it has been 
shown that apolipoproteins are a more important risk 
factor to predispose patients to coronary disease 
[24] 
and therefore should be included in the lipid analysis. 
However, this finding may be a result of the small 
number of athletes who were evaluated based on their 
menstrual dysfunction history. It should be mentioned 
that, we only assessed the female athletes with clinical 
menstrual dysfunction, and based on the new definition 
of the Triad 
[1] athletes with subclinical menstrual 
dysfunction were missed. Therefore we may 
underestimate the prevalence of menstrual dysfunction 
with its complications. 
        Despite the fact that there is not any significant 
correlation of FBS and alteration of BMD in our study, 
HbA1C was inversely correlated with the rate of 
increase in bone mineral density. This inconsistency 
may be due to the small number of our subjects. 
    Limitation in our study should be noted. Firstly, one 
of the limitations of the study was the small number of 
athletes who were evaluated. Because this research 
was designed on the basis of following up of elite 
female athletes with history of clinical menstrual 
dysfunction about two years ago, our study population 
was limited. Therefore we could not add any new  
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patient to increase our sample size. Another limitation 
is the absence of normal athletes as control group to in 
the study. Thirdly, because we cannot supervise on the 
nutritional diet and intensity of exercise of athletes-
with different types of sports-during the study, 
prediction of their energy availability cannot occurr. 
Therefore, their low energy availability as a primary 
contributor to disruptions in menstrual function and 
bone mass was not assessed.   
CONCLUSION 
Based on our finding, there is an inverse relation 
between the rate of increase in bone mineral density of 
spine region and total cholesterol and VLDL levels. 
This result shows that each factor negatively affects 
bone mineral density, that can also impair lipid profile. 
Therefore, chronic hypoestrogenism could be a risk 
factor of cardiovascular disease for adult female 
athletes despite their regular physical activities.  
        However, we recommend that any future study 
should use a better method to identify cases of low 
energy availability and subclinical menstrual disorder 
to find the high risk of athletes earlier. In addition, to 
find the clinical inferences of impaired levels of lipid 
profile among elite female athletes with functional 
hypothalamic menstrual dysfunction, longitudinal 
studies in this group of women should be designed. In 
addition, clinical trial studies should be created to find 
if a high serum concentration of lipid profile is 
reversible after treatment of menstrual dysfunction. 
Moreover, the long-term effects of this condition for 
future risk of cardiovascular diseases are unknown. 
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